VPC-14449 是一种有效和选择性的雄激素受体 DNA 结合结构域 (AR-DBD) 抑制剂,对全长人 AR 的IC50值为 0.34 μM。VPC-14449 可降低全长 AR 以及 AR 变体与染色质相互作用的能力。VPC-14449 可用于前列腺癌的研究。
生物活性 | VPC-14449 is a potent and selective inhibitor of theDNA-binding domain of theandrogen receptor(AR-DBD), withIC50of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostatecancer[1][2]. |
IC50& Target | IC50: 0.34 μM (AR-DBD)[1] |
体外研究 (In Vitro) | VPC-14449 (0.01-100 μM; 24 h) inhibits AR-transcriptional activity and cell viability in LNCaP, C4-2, MR49F, and 22Rv1 cells[2]. VPC-14449 (0.01-100 μM; 24 h) dose-dependently inhibits the transiently expressed full-length human AR in PC3 cells (IC50=0.34 μM) without affecting AR protein expression[1].
Cell Viability Assay[2] Cell Line: | LNCaP, C4-2, MR49F, and 22Rv1 cells | Concentration: | 0.01, 0.1, 10, 100 μM | Incubation Time: | 24 hours | Result: | Suppressed the growth of every tested cell line. |
Western Blot Analysis[2] Cell Line: | LNCaP, C4-2, MR49F, and 22Rv1 cells | Concentration: | 0.01, 0.1, 10, 100 μM | Incubation Time: | 24 hours | Result: | Inhibited endogenous AR transactivation in LNCaP, C4-2 and MR49F cells stimulated with the synthetic androgen R1881. |
|
体内研究 (In Vivo) | VPC-14449 (100 mg/kg; i.p. twice daily for 4 weeks) reduces tumor volume and abolishes PSA production with no decrease in body weight over a total duration 4 weeks in LNCaP xenograft model[1].
Animal Model: | Nude mice (Harlan Sprague-Dawley; 25-31 g; 6-8 weeks) were subcutaneously inoculated with LNCaP cells and castrated[1] | Dosage: | 100 mg/kg | Administration: | I.p. twice daily for 4 weeks | Result: | Suppressed LNCaP tumor volume and blocked serum PSA production. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 125 mg/mL(317.19 mM;Need ultrasonic) 配制储备液 1 mM | 2.5375 mL | 12.6875 mL | 25.3749 mL | 5 mM | 0.5075 mL | 2.5375 mL | 5.0750 mL | 10 mM | 0.2537 mL | 1.2687 mL | 2.5375 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (5.28 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.28 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (5.28 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.28 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (5.28 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.28 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|